Sulaiman Sahabi Kabir, Isma'il Tsiga-Ahmed Fatimah, Musa Muhammad Sale, Makama Bello Tijjani, Sulaiman Abdulwahab Kabir, Abdulaziz Tijjani Bako
Department of Medicine, Yobe State University Teaching Hospital, Damaturu, Nigeria.
Department of Community Medicine, Bayero University Kano/Aminu Kano Teaching Hospital, Kano, Nigeria.
Commun Med (Lond). 2024 Jul 9;4(1):136. doi: 10.1038/s43856-024-00564-1.
Vaccination has been recommended as one of the most potent ways of controlling the mpox (formerly, monkeypox) outbreak, particularly among high-risk groups. Here, we evaluated the prevalence of mpox vaccine acceptance and uptake globally.
We searched multiple databases for peer-reviewed studies published in English from May 2022 to 25th November 2023 that evaluated mpox vaccine acceptance and/or uptake. We fit a random-effects model meta-analysis to calculate the pooled mpox vaccine acceptance and uptake rates, with their 95% confidence intervals (CI) across population outcomes. We performed subgroup analyses among the six World Health Organization (WHO) regions (Africa [AFR], Region of the Americas [AMR], South-East Asia Region [SEAR], European Region [EUR], Eastern Mediterranean Region [EMR], and the Western Pacific Region [WPR]), as well as among select population subgroups.
Of the 2531 studies screened, 61 studies, with a cumulative sample size of 263,857 participants from 87 countries were eligible for inclusion. The overall vaccine acceptance and uptake rates were 59.7% and 30.9% globally. Acceptance and uptake rates among the LGBTQI+ community were 73.6% vs 39.8% globally, 60.9% vs. 37.1% in AMR, 80.9% vs. 50.0% in EUR, and 75.2% vs. 33.5% in WPR. Among PLHIV, vaccine acceptance and uptake rates were 66.4% vs. 35.7% globally, 64.0% vs. 33.9% in AMR, 65.1% vs. 27.0% in EUR, and 69.5% vs. 46.6% in WPR. Among healthcare workers, vaccination intention was 51.0% globally.
Tailored interventions are needed to bolster confidence in the mpox vaccine, maximize vaccine uptake, and increase vaccine access to close the gaps between acceptance and uptake especially among key populations residing in regions with low rates of acceptance and uptake.
疫苗接种已被推荐为控制猴痘（原称猴天花）疫情最有效的方法之一，尤其是在高危人群中。在此，我们评估了全球范围内猴痘疫苗的接受度和接种率。
我们在多个数据库中搜索了2022年5月至2023年11月25日期间以英文发表的、评估猴痘疫苗接受度和/或接种率的同行评审研究。我们采用随机效应模型进行荟萃分析，以计算总体猴痘疫苗接受度和接种率及其在不同人群结果中的95%置信区间（CI）。我们在世卫组织的六个区域（非洲[AFR]、美洲区域[AMR]、东南亚区域[SEAR]、欧洲区域[EUR]、东地中海区域[EMR]和西太平洋区域[WPR]）以及特定人群亚组中进行了亚组分析。
在筛选的2531项研究中，有61项研究符合纳入标准，累计样本量为来自87个国家的263,857名参与者。全球总体疫苗接受度和接种率分别为59.7%和30.9%。全球LGBTQI+群体的接受率和接种率分别为73.6%和39.8%，在美洲区域分别为60.9%和37.1%，在欧洲区域分别为80.9%和50.0%，在西太平洋区域分别为75.2%和33.5%。在艾滋病毒感染者中，全球疫苗接受率和接种率分别为66.4%和35.7%，在美洲区域分别为64.0%和33.9%，在欧洲区域分别为65.1%和27.0%，在西太平洋区域分别为69.5%和46.6%。在医护人员中，全球接种意愿为51.0%。
需要采取针对性的干预措施来增强对猴痘疫苗的信心，最大限度地提高疫苗接种率，并增加疫苗可及性，以缩小接受度和接种率之间的差距，特别是在接受度和接种率较低地区的关键人群中。
